Product Information

ACTEMRA ACTPEN 162 MG/0.9 ML is a brand product labeled by Genentech, Inc., priced at $1279.0578 per ML under NDC 50242014301. Its NADAC has been published 36 times since Oct 22, 2025.

ACTEMRA ACTPEN 162 MG/0.9 ML

tocilizumab
$1279.0578per ML

Strength

162 mg/.9mL

Manufacturer

Genentech, Inc.

NDC

50242014301

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Last Updated

5/20/2026

Active Ingredients

TOCILIZUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA125472

On Market Since

11/19/2018

Pharmacological Classes

Interleukin 6 Receptor Antagonists
Interleukin-6 Receptor Antagonist

Price Statistics

The NADAC for ACTEMRA ACTPEN 162 MG/0.9 ML has been published 36 times since Oct 22, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$1279.0578 per ML
All-time high$1279.0578 (Jun 24, 2026)
All-time low$1273.3755 (Oct 22, 2025)
52-week high$1279.0578
52-week low$1273.3755
Median price$1279.0578
Average price$1277.7951
Largest weekly change+0.4% (Dec 17, 2025)
Weeks tracked36
Tracking sinceOct 22, 2025

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

N/A

3Y

N/A

5Y

N/A

All

+0.4%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 22%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of ACTEMRA ACTPEN 162 MG/0.9 ML?

The current National Average Drug Acquisition Cost (NADAC) for ACTEMRA ACTPEN 162 MG/0.9 ML, manufactured by Genentech, Inc., is $1279.0578 per ML (NDC 50242014301), effective Jun 24, 2026.

How has the price of ACTEMRA ACTPEN 162 MG/0.9 ML changed over time?

Over the history we have for it, the NADAC for ACTEMRA ACTPEN 162 MG/0.9 ML has held within roughly two percent of its current level. It has been tracked across 36 weekly CMS publications since Oct 22, 2025.

What are the highest and lowest recorded NADAC prices for ACTEMRA ACTPEN 162 MG/0.9 ML?

Since Oct 22, 2025, the NADAC for ACTEMRA ACTPEN 162 MG/0.9 ML has ranged from a low of $1273.3755 (Oct 22, 2025) to a high of $1279.0578 (Jun 24, 2026), with a median of $1279.0578 per ML.

Are there cheaper alternatives to ACTEMRA ACTPEN 162 MG/0.9 ML?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, ACTEMRA 162 MG/0.9 ML SYRINGE, is $1001.1205 per ML — about 22% below ACTEMRA ACTPEN 162 MG/0.9 ML.

Who manufactures ACTEMRA ACTPEN 162 MG/0.9 ML?

ACTEMRA ACTPEN 162 MG/0.9 ML (NDC 50242014301) is labeled by Genentech, Inc., and CMS classifies it as a brand product.